Clinical trials: Ondansetron
Schizophrenia
Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia
The purpose of this study is to determine whether improvement in P50 (a pharmacodynamic marker) in auditory sensory gating is demonstrated after administration of TAK-058 and ondansetron compared to placebo in participants with…
- Trial name
- NCT02614586
- Testing
- TAK-058, Ondansetron
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy Participants
Three-way Crossover Study Comparing Ondansetron ODFS Administered With and Without Water to Zofran ODT Without Water
This study conducted in healthy male and female adult participants compared the bioavailability and relative safety and tolerance of a single dose of ondansetron 8 mg Orally Dissolving Filmstrip (ODFS) administered under fasting…
- Trial name
- NCT01220167
- Testing
- Ondansetron 8 mg ODFS without water, Ondansetron 8 mg ODFS with water, Zofran ODT (ondansetron 8 mg) without water
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Aquestive Therapeutics
Irritable Bowel Syndrome With Diarrhea
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
This is a randomized, double-blind, placebo-controlled, 2-arm parallel group study. After qualifying for the study and signing informed consent, patients will undergo a two-week observation period during which stool consistency…
- Trial name
- NCT02757105
- Testing
- BEKINDA
- Where
- 16 sites in United States
- Volunteers
- 127 people
- Sponsor
- RedHill Biopharma Limited
Chemotherapy-induced Nausea and Vomiting
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
The primary study objective is to demonstrate the superiority of APF530 500 mg given subcutaneously (SC) compared with ondansetron 0.15 mg/kg given intravenously (IV) (up to a maximum of 16 mg) in the delayed-phase (> 24-120…
- Trial name
- NCT02106494
- Testing
- APF530, Ondansetron, Fosaprepitant
- Where
- 7 sites in United States
- Volunteers
- 942 people
- Sponsor
- Heron Therapeutics
Postoperative Nausea and Vomiting
Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
The primary objective of this study is to evaluate the efficacy of a single palonosetron IV dose compared to a single ondansetron IV dose in the prevention of postoperative nausea and vomiting through 24 hours after surgery in…
- Trial name
- NCT01395901
- Testing
- Palonosetron, Ondansetron
- Where
- 44 sites in United States, Argentina and 6 more
- Volunteers
- 670 people
- Sponsor
- Helsinn Healthcare SA
Chemotherapy-Induced Nausea and Vomiting
A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)
This study will assess the bioequivalence of a Merck clinical trial formulation of ondansetron compared to a U.S. and non-U.S. marketed formulation of ondansetron.
- Trial name
- NCT00971633
- Testing
- Comparator: Treatment A (Zofran, ondansetron), Comparator: Treatment B (Zofran, ondansetron), Comparator: Treatment C (Zofran, ondansetron)
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Gastroenteritis, Gastritis
BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis
Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (BEKINDA) (Ondansetron 24 mg Bimodal Release Tablets) for Acute Gastroenteritis.
- Trial name
- GUARD (NCT02246439)
- Testing
- RHB-102
- Where
- 26 sites in United States
- Volunteers
- 330 people
- Sponsor
- RedHill Biopharma Limited
Healthy
Two Way Bioequivalence Study Under Fed Conditions
The purpose of this study is to assess the single dose bioequivalence of Ondansetron ODFS 8mg with Zofran ODT® (Containing Ondansetron 8 mg) in healthy, male and female adult, human study participants under fed conditions.
- Trial name
- NCT01217801
- Testing
- Ondansetron (ODFS), Ondansetron (ODT)
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- MonoSol Rx
Healthy
Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions
The objective of this study was to compare the relative bioavailability of the test formulation of Ondansetron HCl with the already marketed reference formulation Zofran® ODT under non-fasting conditions in healthy, non-smoking…
- Trial name
- NCT00934921
- Testing
- Ondansetron, Zofran®
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Nausea and Vomiting, Chemotherapy-Induced
A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
This a Phase III trial designed to determine if IV casopitant plus dexamethasone and ondansetron is more effective in the prevention of vomiting and nausea then dexamethasone and ondansetrone alone following the administration of…
- Trial name
- NCT00601172
- Testing
- Casopitant, Dexamethasone, Ondansetron
- Where
- 96 sites in United States, Belgium and 9 more
- Volunteers
- 710 people
- Sponsor
- GlaxoSmithKline
Nausea and Vomiting, Postoperative, Nausea With Vomiting Chemotherapy-Induced
Crossover Study Comparing Ondansetron Orally Dissolving Film Strip (ODFS) With Zofran Orally Disintegrating Tablets
This was an open-label, balanced, two-treatment, two-period, randomized sequence crossover bioequivalence study with a 7-day washout between periods. Each treatment was administered after an overnight (10 hours) fast.
- Trial name
- 01905/08-09 (NCT01217190)
- Testing
- Ondansetron (ODFS), Zofran (ODT)
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- MonoSol Rx
Chemotherapy-Induced Nausea and Vomiting
Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)
This study will assess the bioequivalence of a Merck clinical trial formulation of ondansetron compared to a non-U.S. marketed formulation of ondansetron.
- Trial name
- NCT00972595
- Testing
- ondansetron clinical trial formulation, ondansetron marketed formulation
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting
Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)
The purpose of this study is to evaluate the efficacy and safety of fosaprepitant (MK-0517) plus ondansetron versus ondansetron alone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric participants…
- Trial name
- NCT02519842
- Testing
- Fosaprepitant, Ondansetron, Dexamethasone
- Volunteers
- 75 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions
The objective of this study was to compare the relative bioavailability of the test formulation of Ondansetron HCl with the already marketed reference formulation Zofran ODT under fasting conditions in healthy, non-smoking adult…
- Trial name
- NCT00934180
- Testing
- Ondansetron, Zofran®
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Postoperative Nausea and Vomiting
Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)
The purpose of this study is to investigate palonosetron versus ondansetron as rescue medication in subjects that develop postoperative nausea and vomiting (PONV) in the Postanaesthesia Care Unit (PACU).
- Trial name
- NCT00967499
- Testing
- Ondansetron, Palonosetron
- Where
- 8 sites in United States
- Volunteers
- 239 people
- Sponsor
- Eisai Inc.
Postoperative Nausea and Vomiting (PONV)
A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery
Some adults are at a higher risk of feeling sick (nausea) or being sick (vomiting) after they have surgery. In this study, these adults will have planned surgery.
- Trial name
- NCT04557189
- Testing
- TAK-951, Ondansetron
- Where
- 7 sites in United States
- Volunteers
- 89 people
- Sponsor
- Takeda
Chemotherapy-Induced Nausea and Vomiting
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
The primary objective is to evaluate the efficacy of two different doses of IV palonosetron in the prevention of chemotherapy induced nausea and vomiting in MEC and HEC patients through 120 hours after start of chemotherapy in…
- Trial name
- NCT01442376
- Testing
- Palonosetron, Ondansetron
- Where
- 67 sites in United States, Argentina and 14 more
- Volunteers
- 502 people
- Sponsor
- Helsinn Healthcare SA